DRI study receives $1.5M grant to investigate the formation of harmful compounds by e-cigarettes

Scientists with the Desert Research Institute (DRI) Organic Analytical Laboratory in Reno, Nev., led by Andrey Khlystov, Ph.D., have been awarded a $1.5M grant from the National Institutes of Health (NIH) to study the formation of dangerous compounds by electronic cigarettes (e-cigarettes).

E-cigarettes have grown in popularity in recent years, and emit nicotine and other harmful compounds including formaldehyde, a dangerous human carcinogen. However, the production of these chemicals may differ across different e-cigarette devices, use patterns, and e-liquid ("juice") formations - and scientists currently lack a thorough understanding of how these chemicals form and how to best test for their presence.

DRI's study, which will run for three years, will test popular e-cigarette types and devices under a wide range of use patterns to resolve questions about harmful and potentially harmful substances produced by e-cigarettes. Among other things, the research team will investigate interactions between flavoring compounds and coils at different ages, temperatures, and e-liquid formations, and how different combinations of power, puff topography, and e-liquid viscosity affect emissions.

This project will identify the most important parameters underlying the formation of harmful and potentially harmful constituents produced by e-cigarettes - and thus help inform the public and policymakers regarding health safety of different e-cigarette devices and e-liquid formulations."

Andrey Khlystov, Ph.D., DRI Organic Analytical Laboratory

Information gained from this project is needed to advise the public on potential health risks of different devices and configurations, to establish standardized testing protocols, and to inform policymakers on regulating certain e-cigarette designs and/or e-liquid constituents.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New Treatment Targets Tumor Microenvironment to Fight Breast Cancer